

Figure1




Figure2





Figure3





Figure4





Figure 5






Table1.Base line characteristics at CDC therapy (n=41)

Characteristics	<i>n (%)</i> or mean $\pm$ SD
Male	21 (51)
Bodyweight (kg)	10.1 $\pm$ 3.0
Age (months)	33 $\pm$ 17
Status	
Post-Glenn	10 (24)
Post-Fontan	31 (76)
Diagnosis	
HLHS and variant HLHS	22 (54)
Asplenia/SV/CAVV	7 (17)
TA(IIc) [†]	2 (4.9)
Polysplenia/SV	2 (4.9)
DORV/hypoplastic LV	2 (4.9)
SLV	2 (4.9)
Others	4 (9.8)

Table2 Adverse events

Event	n(%)	Treatment
ST change	39(95)	Observation
Decreased blood pressure >15mmHg	18(44)	Balloon deflation
Bradycardia >20bpm	5(12)	Balloon deflation
Coronary spasm	8(20)	NTG additional infusion
AMI	0(0)	
VF	0(0)	